ALSEN.PA Sensorion SA (EURONEXT) up 33.82% intraday on high volume: assess next levels

The ALSEN.PA stock jumped 33.82% intraday to €0.736 on 13 Mar 2026 as trading volume surged to 1,300,742 shares. Sensorion SA (ALSEN.PA) traded on EURONEXT in Europe saw a rel volume of 5.26, signalling heavy retail and programmatic activity. Today’s move follows an earnings announcement window and sector rotation in Healthcare. We review the drivers, valuation metrics like EPS -0.09 and PE -7.78, technical overbought signals, and what traders should watch next using Meyka AI-powered market analysis.

ALSEN.PA stock intraday move and volume

Sensorion SA (ALSEN.PA) opened at €0.67 and hit a day high of €0.736 on 13 Mar 2026. Volume reached 1,300,742.00, above the 30-day average of 2,248,614.00, producing a rel volume of 5.26. The one-day jump of 33.82% compressed short interest and pushed price above the 50-day average of €0.34. Traders class this as a high-volume mover event with elevated liquidity and rapid price discovery.

Catalysts and news driving ALSEN.PA stock

Sensorion’s recent communications around clinical programs and the March earnings window likely triggered fresh flows. Market commentaries on Sensorion SA appeared on investing.com, showing heightened coverage and live quotes source. A UK feed mirrored the spike and volume pickup, confirming pan-European attention source. Institutional partnership updates and gene-therapy milestones remain the fundamental backdrop for ALSEN.PA stock momentum.

Financials and valuation for Sensorion SA (ALSEN.PA)

Sensorion SA reports EPS -0.09 and a trailing PE of -7.78, reflecting negative earnings. Market cap stands at €210,235,789.00 with 300,336,842.00 shares outstanding. Key ratios show a strong current ratio of 4.90 and cash per share €0.19, while price-to-book sits near 3.26. These metrics show liquidity strength but high valuation multiples versus biotech peers. Analysts flag cash runway and R&D spending as primary valuation drivers.

Technical picture, momentum and price targets for ALSEN.PA stock

Technicals are extreme: RSI 84.83 and CCI 254.94 indicate overbought conditions. ADX at 41.52 shows a strong trend. Bollinger upper band is €0.57 versus current €0.736, highlighting volatility expansion. Short-term traders may use support at €0.64 and initial resistance near €0.80. We set scenario targets: short-term target €0.80, base 12-month target €0.40, and upside scenario €1.20, each tied to trial results, news flow, and sector re-rating.

Meyka AI rates ALSEN.PA with a score out of 100 and forecast

Meyka AI rates ALSEN.PA with a score of 66.39 out of 100 and issues a B / HOLD suggestion. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects a 12-month price near €0.145, compared with the current price €0.736. That projects an implied downside of -80.30%. Forecasts are model-based projections and not guarantees. Use this with clinical and funding updates when assessing ALSEN.PA stock.

Risks, sector context and trading strategy for ALSEN.PA stock

Key risks include binary clinical outcomes, dilution from capital raises, and biotech sector weakness. Healthcare sector performance is down YTD and shows higher volatility versus broader markets. For active traders, manage size and use stop-loss near €0.60. Long-term investors should monitor cash runway and partnership news. Pair ALSEN.PA stock positions with diversified biotech exposure to offset idiosyncratic risk.

Final Thoughts

ALSEN.PA stock stands out today as a high-volume mover after a 33.82% intraday spike to €0.736 on 13 Mar 2026. The move came with above-average liquidity and clear overbought technicals: RSI 84.83 and ADX 41.52. Fundamentals show cash per share €0.19, EPS -0.09, and market cap €210,235,789.00, underscoring clinical-stage risk and R&D-driven valuation. Meyka AI’s model projects a 12-month level near €0.145, implying -80.30% versus today’s price; that projection is model-based and not a guarantee. For traders, a short-term play targets €0.80 with tight risk controls. For investors, watch clinical readouts, partnerships, and funding before increasing exposure. Use the Meyka AI-powered market analysis tools and company updates to time entries and manage position sizing, given high volatility and event-driven risk in Sensorion SA (ALSEN.PA).

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.